Monomethyl auristatin E and paclitaxel use different mechanisms to alter intracellular calcium signaling.

Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies that deliver cytotoxic agents to cancer cells. Although designed to reduce side effects, ADCs utilizing a microtubule-targeting agent, exemplified by monomethyl auristatin E (MMAE), as the drug cargo, frequently induce chemotherapy-induced peripheral neuropathy (CIPN) at rates comparable to taxanes like paclitaxel (PTX). Despite their clinical success, ADC-associated neurotoxicity remains a significant challenge, necessitating a deeper mechanistic understanding and potential neuroprotective strategies.

A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy.

Dramatic improvements in cancer survival have occurred in the last decade, but the quality of life for many survivors is compromised due to severe, long-lasting, and often irreversible side effects of chemotherapy. The neurological side effects, chemotherapy induced peripheral neuropathy (CIPN) and cancer related/induced cognitive impairment (CRCI/CICI), are under-recognized and can occur after chemotherapy, immunotherapy, or radiation. The cellular mechanisms underlying these neurological side effects are poorly understood and there are no effective treatments or preventions, other than reduction or termination of cancer therapy.

The Impact of Mutations in Wolframin on Psychiatric Disorders.

Wolfram Syndrome is a rare autosomal recessive disease characterized by early-onset diabetes mellitus, neurodegeneration, and psychological disorders. Mutations in the gene , coding for the protein wolframin, cause Wolfram Syndrome and are associated with bipolar disorder and schizophrenia. This report aims to connect mutations to their impact on protein expression and structure, which ultimately translates to altered cell function and behavioral alterations of an individual.